Table 3. Proportions of cases of sequelae attributable to Campylobacter spp., Salmonella sp. or enterohaemorrhagic Escherichia coli.

Pathogen, sequelae	Attributable proportion, % of cases of sequelae, (95% UI)	No. of studies	Country
Campylobacter spp.
Guillain-Barré syndrome	0.03 (0.02–0.06)	3	Netherlands, Sweden
Inflammatory bowel disease	0.30 (0.27–0.34)	2	Denmark, Sweden
Reactive arthritis	5.01 (2.60–8.08)	14	Denmark, Finland, Netherlands, Norway, United Kingdom, USA
Salmonella sp.
Inflammatory bowel disease	0.43 (0.38–0.48)	2	Denmark, Sweden
Reactive arthritis	6.09 (2.81–10.47)	12	Australia, Denmark, Finland, Netherlands, Switzerland, United Kingdom, USA
EHEC
Haemorrhagic colitis	9.14 (4.17–15.51)	2	Germany, United Kingdom
Haemolytic uraemic syndrome	6.13 (4.61–7.82)	23	Austria, Belgium, Canada, Denmark, Finland, Germany, Hungary, Slovakia, United Kingdom, USA

EHEC: enterohaemorrhagic Escherichia coli; UI: uncertainty interval; USA: United States of America.

Sources: Data drawn from the results of identified studies.^21–69